Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 41.51% is in line with its 5-year average of 44.33%, around the middle of its 5-year range (31.58%–50.79%).
1.22% below its 12-month average of 42.02%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 31.58%.
GROSS MARGIN
41.51%
GROSS MARGIN AVG TTM
42.02%
GROSS MARGIN AVG 3Y
44.71%
GROSS MARGIN AVG 5Y
44.33%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.22%
CURRENT VS 3Y AVG
-7.16%
CURRENT VS 5Y AVG
-6.36%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+0.31%
vs the sector median at left
Spectral AI, Inc.
Market Cap
$52.99M
Gross Margin
41.51%
TTM Avg
42.02%
3Y Avg
44.71%
5Y Avg
44.33%
Market Cap
$53.12M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$52.60M
Gross Margin
20.51%
TTM Avg
34.75%
3Y Avg
47.46%
5Y Avg
49.68%
Market Cap
$53.71M
Gross Margin
44.89%
TTM Avg
72.44%
3Y Avg
36.22%
5Y Avg
57.48%
Market Cap
$51.43M
Gross Margin
-29.12%
TTM Avg
13.64%
3Y Avg
-48.92%
5Y Avg
-105.92%
Market Cap
$50.99M
Gross Margin
-262.66%
TTM Avg
-246.22%
3Y Avg
-188.06%
5Y Avg
-150.05%
Market Cap
$50.66M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spectral AI, Inc. (MDAI) | $52.99M | 41.51% | 42.02% | 44.71% | 44.33% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.12M | 0.00% | 0.00% | 0.00% | 0.00% |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $52.60M | 20.51% | 34.75% | 47.46% | 49.68% |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $53.71M | 44.89% | 72.44% | 36.22% | 57.48% |
| eXoZymes, Inc. (EXOZ)vs › | $51.98M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aldeyra The (ALDX)vs › | $54.46M | 0.00% | 0.00% | 0.00% | 0.00% |
| ImageneBio Inc (IMA)vs › | $51.43M | -29.12% | 13.64% | -48.92% | -105.92% |
| Envoy Medical, Inc. (COCH)vs › | $50.99M | -262.66% | -246.22% | -188.06% | -150.05% |
| Tenax Therapeutics, Inc. (TENX)vs › | $50.66M | 0.00% | 0.00% | 0.00% | 0.00% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.00M | N/A | 50.00% | 25.00% | 16.67% |
Gross Margin
41.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 31.58% |
| 2026-03-31 | 50.79% |
| 2025-12-31 | 39.78% |
| 2025-09-30 | 42.75% |
| 2025-06-30 | 45.21% |
| 2025-03-31 | 47.23% |
| 2024-12-31 | 44.03% |
| 2024-09-30 | 44.87% |
| 2024-06-30 | 44.32% |
| 2024-03-31 | 46.55% |
| 2023-12-31 | 46.08% |
| 2023-09-30 | 42.79% |
| 2023-06-30 | 42.13% |
| 2023-03-31 | 42.95% |
| 2022-12-31 | 41.14% |
| 2022-09-30 | 45.85% |
| 2022-06-30 | 42.44% |
| 2022-03-31 | 40.90% |
| 2021-12-31 | 46.24% |
| 2021-09-30 | 46.24% |
